Adding Carvediol Therapy Prevents Progression of Chronic Kidney Disease: Presented at ASNBy Bryan DeBusk, PhD
SAN FRANCISCO, CA -- November 6, 2007 -- Patients with stage 3 chronic kidney disease (CKD) who receive carvediol in addition to their other prescribed therapies are 29.8% less likely to progress to stage 4 CKD over a 3-year period.
Naoyuki Nakao, MD, a clinician in the Division of Nephrology and Dialysis, Kohnan Hospital, Kobe, Japan, reported the findings here at the 40th Annual American Society of Nephrology (ASN) meeting.
Dr. Nakao and colleagues randomised 245 patients with stage 3 or stage 4 CKD into two groups to receive placebo (n = 122) or 3.75 to 30 mg carvediol (n = 123) 3 times a day.
Patients were followed for 3 years to examine time of doubling of serum creatinine and time to progression of end stage renal disease (ESRD).
Following adjustments for baseline blood pressure, rate of daily urinary protein production, renal function, and diabetes, patients receiving carvediol had a.70 relative risk for doubling serum creatinine and progressing to ERSD (95% confidence interval [CI].56 to.80, P =.009).
An additional reduction in heart rate was observed in the group receiving carvediol (P =.01), but no difference was noted in blood pressure between the two groups.
Dr. Nakao also noted that carvediol significantly reduced the number of cardiovascular disease events despite the underlying CKD stage.
Although the effects on progression to more severe CKD were primarily limited to individuals with stage 3 CKD, Dr. Nakao concluded that, "carvediol should be considered another tool for better management of those at high risk."
[Presentation Title: A Randomized Trial of the b-adrenergic Antagonist Carvediol in Chronic Kidney Disease (CCARE Trial). Abstract SA-FC039]
http://www.docguide.com/news/content.nsf/news/852571020057CCF68525738B0067666A
I Hate Dialysis Message Board
Author
